These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16264167)

  • 1. When (not) to stop a clinical trial for benefit.
    Pocock SJ
    JAMA; 2005 Nov; 294(17):2228-30. PubMed ID: 16264167
    [No Abstract]   [Full Text] [Related]  

  • 2. Stopping trials for benefit can (sometimes) benefit patients.
    Pater JL; Goss P; Meyer R
    J Clin Oncol; 2008 Jun; 26(16):2787-8; author reply 2788. PubMed ID: 18509191
    [No Abstract]   [Full Text] [Related]  

  • 3. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to clinical trial data. Data monitoring committees and selective outcome reporting.
    Ting JY
    BMJ; 2011 Feb; 342():d635. PubMed ID: 21285218
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical trial registration.
    Harms M
    Physiotherapy; 2011 Sep; 97(3):181. PubMed ID: 21820534
    [No Abstract]   [Full Text] [Related]  

  • 6. EU clinical trials directive: 0% inspiration, 100% perspiration?
    Lancet Neurol; 2004 Jun; 3(6):321. PubMed ID: 15157844
    [No Abstract]   [Full Text] [Related]  

  • 7. Stopping clinical trials early.
    Grant A
    BMJ; 2004 Sep; 329(7465):525-6. PubMed ID: 15345605
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancing the Scientific Integrity and Safety of Clinical Trials: Recommendations for Data Monitoring Committees.
    Lewis RJ; Calis KA; DeMets DL
    JAMA; 2016 Dec; 316(22):2359-2360. PubMed ID: 27960001
    [No Abstract]   [Full Text] [Related]  

  • 9. Should you join a clinical trial?
    Johns Hopkins Med Lett Health After 50; 2005 Mar; 17(1):6-7. PubMed ID: 15742482
    [No Abstract]   [Full Text] [Related]  

  • 10. A probiotics trial on trial: the problem of timely detection of adverse advents in therapeutic trials.
    Giard RW
    J Clin Epidemiol; 2010 Apr; 63(4):347-9. PubMed ID: 19762211
    [No Abstract]   [Full Text] [Related]  

  • 11. [Constraints on publication rights in industry-initiated clinical trials--secondary publication].
    Gøtzsche PC; Hróbjartsson A; Johansen HK; Haahr MT; Altman DG; Chan AW
    Ugeskr Laeger; 2006 Jun; 168(25):2467-9. PubMed ID: 16824372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constraints on publication rights in industry-initiated clinical trials.
    Gøtzsche PC; Hróbjartsson A; Johansen HK; Haahr MT; Altman DG; Chan AW
    JAMA; 2006 Apr; 295(14):1645-6. PubMed ID: 16609085
    [No Abstract]   [Full Text] [Related]  

  • 13. Overseeing of clinical research.
    Greenberg D
    Lancet; 2001 Dec; 358(9298):2087. PubMed ID: 11755654
    [No Abstract]   [Full Text] [Related]  

  • 14. [Data monitoring committees. Third pillar in the methodical conduct of clinical trials].
    Fischer T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):793-6. PubMed ID: 18563280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The need for expanded monitoring of adverse events in behavioral health clinical trials.
    Peterson AL; Roache JD; Raj J; Young-McCaughan S;
    Contemp Clin Trials; 2013 Jan; 34(1):152-4. PubMed ID: 23117077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who's minding the data? Data Monitoring Committees in clinical cancer trials.
    Keating P; Cambrosio A
    Sociol Health Illn; 2009 Apr; 31(3):325-42. PubMed ID: 19055588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [DSMB. 2. The importance of an efficient DSMB: some examples of high-risk clinical trials].
    Brun-Buisson C
    Med Sci (Paris); 2005 Feb; 21(2):187-9. PubMed ID: 15691491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stopping guidelines for harm in a study designed to establish the safety of a marketed drug.
    Fleishman AN; Parker RA
    J Biopharm Stat; 2012; 22(2):338-50. PubMed ID: 22251178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.